Dr. Laurence Klotz, a urological oncologist and scientist at Sunnybrook who specializes in prostate cancer care and research, is a participating investigator.

For the Canadian Prostate Cancer Biomarker Network's studies, Dr. Klotz and his lab team will develop a tissue microarray from a cohort of patients of the Sunnybrook active surveillance program, the most mature program of its kind in the world. These patients are considered stable with 10 to 15 years of follow-up with no required treatment. The tissue microarray based on this cohort will form a control group for these biomarker studies to help look for aggressive disease.

Tissue microarrays can house up to 1,000 separate tissue cores taken from tumour samples, or in this case from clinical biopsies. These tissue cores are assembled in an array format to allow for multiplex histological (pathology) analysis.

Topics

Next story

| Learn More

Discover content from The Globe and Mail that you might otherwise not have come across. Here we’ll provide you with fresh suggestions where we will continue to make even better ones as we get to know you better.

You can let us know if a suggestion is not to your liking by hitting the ‘’ close button to the right of the headline.